Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

CAPS Rating: 2 out of 5

The Company is a biopharmaceutical company that discovers, develops, and intends to commercialize pharmaceutical products for the treatment of serious medical conditions.

Results 1 - 20 of 42 : 1 2 3 Next »

Recs

0
Member Avatar trackjakeambrose (60.53) Submitted: 7/20/2014 10:06:15 PM : Outperform Start Price: $306.20 REGN Score: -1.70

1 ;-)

Recs

0
Member Avatar marsuculix (< 20) Submitted: 7/7/2014 8:40:30 AM : Outperform Start Price: $309.20 REGN Score: -2.89

IMO Eylea market potential is underestimated by the market...

Recs

0
Member Avatar SqwiiTrader (46.90) Submitted: 5/7/2014 6:06:24 PM : Underperform Start Price: $310.40 REGN Score: +2.16

Biotech bull market top

Recs

0
Member Avatar Jbshow (< 20) Submitted: 4/29/2014 6:18:44 PM : Outperform Start Price: $278.42 REGN Score: +3.27

Regeneron has some leading drugs that will get a boost from the aging baby generation.

Recs

1
Member Avatar TMFTycoon (31.74) Submitted: 3/20/2014 3:53:53 PM : Outperform Start Price: $328.69 REGN Score: -13.46

Things are looking good for Eylea, one of Regeneron's drugs, and it is scheduled for further regulatory decisions and Phase III testing later this year.

Recs

0
Member Avatar Chemdawg (69.50) Submitted: 3/7/2014 2:07:49 AM : Outperform Start Price: $341.83 REGN Score: -16.37

12 shots in the eye per year Vs 52 shots in the eye for the competition ....which would you choose?

Recs

0
Member Avatar d3ming (30.71) Submitted: 1/31/2014 1:30:34 PM : Outperform Start Price: $291.02 REGN Score: -7.07

zzporte

Recs

0
Member Avatar stocklade (23.17) Submitted: 1/17/2014 1:28:35 AM : Outperform Start Price: $290.92 REGN Score: -3.61

Macular increasing as population ages.

Recs

0
Member Avatar ForgetGold (< 20) Submitted: 1/15/2014 6:44:27 PM : Outperform Start Price: $287.72 REGN Score: -2.34

Research and development. Cutting edge products

Recs

0
Member Avatar 1badbeerad (45.05) Submitted: 12/30/2013 12:12:18 AM : Outperform Start Price: $277.01 REGN Score: +1.52

A runner.

Recs

0
Member Avatar dschmedeke (< 20) Submitted: 12/7/2013 12:13:39 AM : Outperform Start Price: $284.52 REGN Score: -2.83

Regn has many unique products in the pipeline including Elyla and has partnered with Bayer in Europe.

Recs

1
Member Avatar davidm9999 (< 20) Submitted: 11/11/2013 2:51:06 PM : Underperform Start Price: $279.55 REGN Score: +3.51

Given its precipitous rise, REGN is due for a correction. Its PE has been gamed using a $470M tax credit to bring it from 53 to 40. Further, the company's blockbuster product Eylea has generated substantial sales, over the past two years, leading to the appearance of success. However, the company's upcoming products do not have the same footing as Eylea and are not ready for market. In order for REGN to maintain its upward climb, it would need a product like Eylea to be put onto market immediately. This could drive its price further, as high as $495 per share, however, macro conditions are as much a factor and Regeneron's innovations. If you are going to play the market, I suggest you play Regeneron. If the market goes south, Regeneron will lead it there

Recs

1
Member Avatar biostrategy (< 20) Submitted: 10/23/2013 7:34:43 AM : Underperform Start Price: $305.95 REGN Score: +14.31

Good company but at more than 7 times sales in a niche market it could be in overheated territory right now.

Recs

0
Member Avatar 1russianguy (59.98) Submitted: 10/9/2013 2:10:38 PM : Outperform Start Price: $278.17 REGN Score: -10.67

Liked by Hilary Kramer. Coming with replacement of lipitor, which 70% of doctors will be subscribing. Buy long-term on pull back.
http://www.bloomberg.com/video/hilary-kramer-s-healthcare-play-RWxPwyIHT_CPhQrCnHr_1w.html

Recs

1
Member Avatar paek813 (99.50) Submitted: 9/26/2013 5:08:39 PM : Outperform Start Price: $228.92 REGN Score: +12.19

s&p 4 star:

August 19, 2013

S&P RAISES OPINION ON SHARES OF REGENERON PHARMA TO BUY FROM HOLD ON VALUATION (REGN 229.56 ****):

We keep our forward P/E-based target price at $284, but now view REGN's valuation as attractive following a 15% decline since reporting Q2 earnings earlier this month. We attribute the share price weakness to signs of moderating sales growth of Eylea for eye disease wet AMD. While we expect long-term competition for the franchise, we see its approval for diabetes macular edema, likely by '15, providing a long-term growth driver. We also anticipate robust news flow from its clinical pipeline over the coming months, led by Phase III candidate Alirocumab for high cholesterol.
/S.Silver

~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~

August 29, 2013

REGN announces Eylea (aflibercept) Injection has been approved by the European Commission for the treatment of visual impairment due to Macular Edema Secondary to Central Retinal Vein Occlusion (CRVO).

~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~

Today:

RBC says increased likelihood of a bill increasing FDA's power to regulate compounding pharmacies, especially those who produce large volumes of compounded drug and ship them across state lines, increases the likelihood of a shift away from Avastin to REGN's Eylea. Maintains outperform.

Recs

0
Member Avatar 1picks (84.68) Submitted: 9/24/2013 10:08:03 AM : Outperform Start Price: $294.69 REGN Score: -14.22

Liked by Hilary Kramer. Coming with replacement of lipitor, which 70% of doctors will be subscribing. Buy long-term on pull back.
http://www.bloomberg.com/video/hilary-kramer-s-healthcare-play-RWxPwyIHT_CPhQrCnHr_1w.html

Recs

0
Member Avatar Elmer22003 (35.66) Submitted: 9/18/2013 10:51:17 PM : Outperform Start Price: $309.91 REGN Score: -16.53

MONSTER. Yes, REGN has done nothing but go through the roof but there is still HUGE potential here. Unbelievable pipeline. REGN will is overweight and will be in 400's before 2015.

Recs

0
Member Avatar pramathmalik (47.75) Submitted: 7/2/2013 4:03:02 AM : Outperform Start Price: $230.14 REGN Score: +8.50

Cramer

Recs

3
Member Avatar zzlangerhans (99.69) Submitted: 5/15/2013 10:52:29 PM : Outperform Start Price: $281.81 REGN Score: -12.72

I originally laid out a very compelling thesis for buying Regeneron when the share price was below 50, and came very close to buying it but the stock never met my arbitrary GBMB threshold. Now I find myself buying 30 shares for the #zzporte collaboration at 280, which is rather infuriating. Nevertheless, it's a good reminder that one of the psychological inhibitors of outperformance is reluctance to buy a stock just because a low was missed. Stocks shouldn't be bought just because they're going up, but they shouldn't be boycotted for that reason either.

Aside from the massive sales outperformance of Eylea, Regeneron has numerous late stage compounds in development including sarilumab for rheumatoid arthritis and alirocumab for hypercholesterolemia. They are also in late stage trials to broaden the indications for Eylea. Now that quarterly revenues are approaching half a billion dollars and the market cap has passed 27 billion, I don't feel well-qualified to make a fair value assessment so I'm limited to following Portefeuille's recommendation here.

Recs

1
Member Avatar ChipNPutt11 (65.96) Submitted: 4/29/2013 3:58:12 PM : Outperform Start Price: $215.48 REGN Score: +16.04

Very well run, finally a marketable product in Eylea. Great pipeline. I've owned since 1997, mainly because Dr. Roy Vagelos got invovled after retiring from Merck. He attracted a lot of early funding. They comapny is expanding their R&D and headquaters facility in Tarrytown and adding 400 to staff. Plenty of funding deals available for them now.

Results 1 - 20 of 42 : 1 2 3 Next »

Featured Broker Partners


Advertisement